As Capan-2 originates lymph node metastasis from a well-differentiated cancer49, this could represent variable AHNAK2 expression based on tumour grade and may indicate suitability as a therapeutic target in specific tumour stage and mutational burden. Here, AHNAK2 is linked to neoplasm.